Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Argus Health
Express Scripts
Fuji
UBS
Accenture
Cipla
Cantor Fitzgerald
Farmers Insurance
AstraZeneca

Generated: January 18, 2018

DrugPatentWatch Database Preview

Roche Company Profile

« Back to Dashboard

Summary for Roche
International Patents:82
US Patents:3
Tradenames:50
Ingredients:46
NDAs:64

Drugs and US Patents for Roche

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche Palo CELLCEPT mycophenolate mofetil SUSPENSION;ORAL 050759-001 Oct 1, 1998 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Roche ENDEP amitriptyline hydrochloride TABLET;ORAL 083639-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Roche TARACTAN chlorprothixene TABLET;ORAL 012486-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Roche TARACTAN chlorprothixene TABLET;ORAL 012486-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Roche KONAKION phytonadione INJECTABLE;INJECTION 011745-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Roche Palo CELLCEPT mycophenolate mofetil hydrochloride INJECTABLE;INJECTION 050758-001 Aug 12, 1998 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Roche COACTIN amdinocillin INJECTABLE;INJECTION 050565-003 Dec 21, 1984 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Roche VALIUM diazepam TABLET;ORAL 013263-006 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Roche ENDEP amitriptyline hydrochloride TABLET;ORAL 085303-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Roche ENDEP amitriptyline hydrochloride TABLET;ORAL 083639-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Roche

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche KLONOPIN RAPIDLY DISINTEGRATING clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 020813-005 Dec 23, 1997 ➤ Subscribe ➤ Subscribe
Roche RIMADYL carprofen TABLET;ORAL 018550-002 Dec 31, 1987 ➤ Subscribe ➤ Subscribe
Roche HIVID zalcitabine TABLET;ORAL 020199-002 Jun 19, 1992 ➤ Subscribe ➤ Subscribe
Roche Palo CELLCEPT mycophenolate mofetil TABLET;ORAL 050723-001 Jun 19, 1997 ➤ Subscribe ➤ Subscribe
Roche Palo CELLCEPT mycophenolate mofetil hydrochloride INJECTABLE;INJECTION 050758-001 Aug 12, 1998 ➤ Subscribe ➤ Subscribe
Roche Palo CYTOVENE ganciclovir sodium INJECTABLE;INJECTION 019661-001 Jun 23, 1989 ➤ Subscribe ➤ Subscribe
Roche HIVID zalcitabine TABLET;ORAL 020199-001 Jun 19, 1992 ➤ Subscribe ➤ Subscribe
Roche KLONOPIN clonazepam TABLET;ORAL 017533-002 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Roche VALRELEASE diazepam CAPSULE, EXTENDED RELEASE;ORAL 018179-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Roche TEGISON etretinate CAPSULE;ORAL 019369-002 Sep 30, 1986 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ROCHE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Suspension 6 mg/mL ➤ Subscribe 6/18/2015
➤ Subscribe Capsules 30 mg and 45 mg ➤ Subscribe 8/2/2011
➤ Subscribe For Oral Suspension 200 mg/mL ➤ Subscribe 3/25/2011
➤ Subscribe Capsule 75 mg ➤ Subscribe 11/15/2010
➤ Subscribe Injection 1 mg/mL, 3 mL Vial ➤ Subscribe 8/31/2007
➤ Subscribe Tablets 2.5 mg and 150 mg ➤ Subscribe 5/16/2007
➤ Subscribe Injection 0.1 mg/mL, 1 mL single dose vial ➤ Subscribe 3/8/2007
➤ Subscribe Injection 1 mg/mL, 4 mL multi-dose vials ➤ Subscribe 7/19/2004
➤ Subscribe Injection 1 mg/mL, 1 mL vials ➤ Subscribe 6/1/2004

Non-Orange Book US Patents for Roche

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,952,375 Compounds and methods for synthesis and therapy ➤ Subscribe
6,225,341 Compounds and methods for synthesis and therapy ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Roche Drugs

Supplementary Protection Certificates for Roche Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90024-9 Sweden ➤ Subscribe
2014038 Lithuania ➤ Subscribe PRODUCT NAME: UMECLIDINIUM BROMIDIUM; REGISTRATION NO/DATE: EU/1/14/922 20140428
C0022 France ➤ Subscribe PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
C0052 France ➤ Subscribe PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
1740177/02 Switzerland ➤ Subscribe PRODUCT NAME: UMECLIDINIUM BROMID + VILANTEROL; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014
90018-6 Sweden ➤ Subscribe PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
14/058 Ireland ➤ Subscribe PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516
90020-1 Sweden ➤ Subscribe PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
C/GB02/042 United Kingdom ➤ Subscribe PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418
00694 Netherlands ➤ Subscribe PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Fish and Richardson
Healthtrust
McKinsey
McKesson
Deloitte
Daiichi Sankyo
Baxter
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot